Latest Breaking News On - கிநிர் மருந்துகள் - Page 1 : comparemela.com

iCrowdNewswire   Jan 26, 2021  9:00 AM ET Support for preclinical testing for a novel broad spectrum inhaled anti-infective that rapidly eradicates microbial biofilms which are present in the lungs of Cystic Fibrosis patients DUBLIN,OHIO (26 January 2021) Kinnear Pharmaceuticals (Kinnear)announces an agreement with the Cystic Fibrosis Foundation on a staged Therapeutic Development Award (TDA) providing development funds for Kinnear’s lead compound, CSA-131. The staged award of up to $3 million, supported with matching funds from Kinnear, provides funding for preclinical research to enable the filing of an Investigational New Drug (IND) application with the FDA in 2022. “We are pleased and honored to announce this agreement with the Cystic Fibrosis Foundation to help progress CSA-131 as a novel therapeutic drug candidate for CF lung infections. Individuals living with CF are frequently burdened with life-threatening lung infections resulting from highly drug-resistant bacte

Carl genbergKinnear pharmaceuticalsCystic fibrosis foundationTherapeutic development awardCystic fibrosisInvestigational new drugChief executive officerCerashield endotracheal tubeRelations contactsRespiratory infectionsInhaled drugFinancial marketகிநிர் மருந்துகள்சிஸ்டிக் ஃபைப்ரோஸிஸ் அடித்தளம்சிகிச்சை வளர்ச்சி விருதுசிஸ்டிக் ஃபைப்ரோஸிஸ்